MannKind Corporation stock rating and score history
All changes in ratings, performance and outlook tracked over time.
MannKind Corporation stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does MannKind Corporation do? Business model and key facts
Get the full picture of MannKind Corporation: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 403
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Stocks related to MannKind Corporation
Selected based on industry alignment and relative market positioning.
Events and news impacting MannKind Corporation stock
Earnings, coporate decisions and industry developments that can affect the share price.
MannKind Corporation fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
